Posts Tagged ‘cardiovascular outcomes’

ECO2024: Four Years of Semaglutide Heart and Weight Benefits

May 14, 2024 — How long? So many questions about advanced obesity medicines center on this line of inquiry. How long must I take these medicines, how long will their benefits last. Yesterday we learned at ECO2024 that four years of semaglutide offers impressive benefits for a person’s weight and heart health. Nature Medicine published data on weight outcomes […]

Indication for Heart Health Marks a New Era in Obesity Treatment

March 9, 2024 — It’s official. FDA now says that semaglutide, in doses used to treat obesity, can prevent heart attacks, strokes, and deaths in persons with cardiovascular disease and overweight or obesity. This is nothing short of the dawn of a new era in obesity treatment. FDA Division Director John Sharretts said it clearly: “This patient population has […]

The Best and Worst of 2023 in Obesity and Health

December 28, 2023 — This was a year of great progress in obesity, and with that progress came frustrations and angst. So finding the best and worst of 2023 in obesity and health is actually quite an easy and interesting task. Let’s dig right in. #1 Best: Cardiovascular Outcomes Benefit Data for Semaglutide Above all else the landmark findings […]

A Conversation with Dr. Ania Jastreboff About the SELECT Trial

November 16, 2023 — It was an amazing moment. Hundreds upon hundreds people packed into huge convention hall to hear about the detailed outcomes of the first ever randomized controlled trial to show that treating obesity could prevent heart attacks, strokes, and cardiovascular deaths. The implications of the SELECT trial for obesity care will be enormous and we had […]

Three Details Worth Knowing About the SELECT Study

November 12, 2023 — For some time to come, we will be learning more and more about the details and implications of the landmark SELECT study published yesterday in NEJM and presented at the American Heart Association Scientific Sessions in Philadelphia. A massive crowd packed the meeting hall yesterday for good reason. These results will change the practice of […]

The SELECT Study Makes One Thing Undeniable

November 11, 2023 — Newly published in full, the results of the SELECT study of semaglutide for cardiovascular outcomes in persons with obesity but not diabetes makes one thing undeniable. Obesity is a chronic, treatable disease. Treating obesity requires more than just telling a person to change their lifestyle. It involves addressing the disease pathology that is at work, […]

Caught Between Confronting Reality and Claiming Autonomy

November 11, 2023 — It has long been a struggle – one of confronting the biological reality of obesity while claiming autonomy and embracing our own identity. Having our eyes wide open about obesity and health while we tell people who want to impose their judgments on us to buzz off. This is my body and my life. Puritans […]

The Intersection of Heart, Kidney, and Metabolic Outcomes

October 13, 2023 — The handwriting is on the wall. Insurers can’t avoid covering obesity drugs forever, said a recent analysis from Bloomberg and they were right. What prompted that conclusion is the cascade of health outcome studies that make it unmistakeable. Treating obesity and and related metabolic diseases with advanced medicines like semaglutide has a dramatic effect on […]

A Jaw-Dropping Spike in Obesity-Related Heart Deaths

September 9, 2023 — Two years ago, we got the first signal. It looked like deaths due to heart disease were no longer dropping. In fact, they went up in 2020. This week, the reason why became pretty clear. A new study in the Journal of the American Heart Association documented a tripling of obesity-related heart deaths over the […]

Preventing Heart Attacks, Strokes, and Deaths by Treating Obesity

August 21, 2023 — How much might the application of new insights from the SELECT study of treating obesity do for preventing heart attacks, strokes, and deaths. A first pass at answering this question appeared in Cardiovascular Drugs and Therapy last week. Nathan Wong, Hridhay Karthikeyan, and Wenjun Fan estimated the potential for semaglutide treatment to lower cardiovascular disease […]